Bio-Techne (TECH) 주식 개요
Bio-Techne Corporation은 자회사와 함께 전 세계 연구, 진단 및 바이오 프로세싱 시장을 위한 생명과학 시약, 기기 및 서비스를 개발, 제조 및 판매하고 있습니다. 자세히 보기
TECH Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bio-Techne Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$72.12 |
| 52주 최고가 | US$72.62 |
| 52주 최저가 | US$43.20 |
| 베타 | 1.28 |
| 1개월 변동 | -0.15% |
| 3개월 변동 | 33.56% |
| 1년 변동 | 40.69% |
| 3년 변동 | -2.08% |
| 5년 변동 | -46.01% |
| IPO 이후 변동 | 11,157.76% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Aug 12
TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced Outlook
Analysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.
내러티브 업데이트 • Jul 29
TECH: Merger Premium And Deal Uncertainty Will Restrain Future Earnings Appeal
Analysts have nudged their price target for Bio-Techne higher to reflect a shift in fair value from $55.05 to $56.51. This change is supported by updated assumptions for revenue growth, profit margins and future P/E levels, as well as a slightly lower discount rate.
내러티브 업데이트 • Jul 15
TECH: AI Protein Expansion And Portfolio Rebrand Will Support Balanced Long-Term Upside
Analysts have reduced their price target on Bio-Techne to $73 from $75, reflecting updated assumptions about the balance between revenue growth expectations, lower projected profit margins, and a slightly higher future P/E multiple. What’s in the News for Bio-Techne Bio-Techne and Merck KGaA agreed to a definitive acquisition deal in which Merck KGaA plans to acquire Bio-Techne for US$73 per share in cash, valuing the company at about US$11.5b and implying an enterprise value of roughly US$11.3b, with the transaction subject to regulatory and shareholder approvals and customary closing conditions.내러티브 업데이트 • Jul 01
TECH: Pending Merger Premium Will Constrain Future Earnings Appeal
Bio-Techne's updated analyst price target has been trimmed from about $56.78 to $55.05, as analysts factor in slightly higher assumed revenue growth and P/E levels, along with modestly lower profit margin estimates. What’s in the News for Bio-Techne Merck KGaA agreed to acquire Bio-Techne in an all cash transaction valued between US$11.3b and US$11.5b, which Merck states represents about a 36% premium to Bio-Techne’s trading price at announcement.분석 기사 • Jun 18
Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration
Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...내러티브 업데이트 • Jun 17
TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin Upside
Analysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.내러티브 업데이트 • Jun 03
TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward Outlook
Analysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple. What's in the News Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.내러티브 업데이트 • May 12
TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future Upside
Analysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).내러티브 업데이트 • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.내러티브 업데이트 • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).내러티브 업데이트 • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).내러티브 업데이트 • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).내러티브 업데이트 • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.분석 기사 • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...내러티브 업데이트 • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).내러티브 업데이트 • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).내러티브 업데이트 • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).내러티브 업데이트 • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.내러티브 업데이트 • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).분석 기사 • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...내러티브 업데이트 • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.내러티브 업데이트 • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.내러티브 업데이트 • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha주주 수익률
| TECH | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | -0.4% | -3.8% | -2.2% |
| 1Y | 40.7% | 20.7% | 13.1% |
수익률 대 산업: TECH은 지난 1년 동안 20.7%의 수익을 기록한 US Life Sciences 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: TECH은 지난 1년 동안 13.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| TECH volatility | |
|---|---|
| TECH Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: TECH는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: TECH의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1976 | 3,000 | Kim Kelderman | www.bio-techne.com |
바이오테크네 코퍼레이션(Bio-Techne Corporation)은 자회사들과 함께 전 세계 연구, 진단 및 바이오프로세싱 시장을 대상으로 생명과학 시약, 장비 및 서비스를 개발, 제조 및 판매하고 있습니다. 이 회사는 ‘단백질 과학(Protein Sciences)’과 ‘진단 및 공간 생물학(Diagnostics and Spatial Biology)’이라는 두 가지 사업 부문을 통해 운영되고 있습니다. 단백질 과학(Protein Sciences) 부문은 사이토카인 및 성장 인자, 항체, 소분자, 조직 배양 혈청, 세포 선별 기술 등 생명과학 연구, 진단, 세포 및 유전자 치료의 다양한 분야에 사용되는 생물학적 시약을 개발 및 제조합니다.
Bio-Techne Corporation 기초 지표 요약
| TECH 기초 통계 | |
|---|---|
| 시가총액 | US$11.30b |
| 순이익 (TTM) | US$181.84m |
| 매출 (TTM) | US$1.22b |
62.2x
주가수익비율(P/E)9.3x
주가매출비율(P/S)TECH는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| TECH 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.22b |
| 매출원가 | US$410.16m |
| 총이익 | US$804.88m |
| 기타 비용 | US$623.04m |
| 순이익 | US$181.84m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 1.16 |
| 총이익률 | 66.24% |
| 순이익률 | 14.97% |
| 부채/자본 비율 | 9.5% |
TECH의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.4%
현재 배당 수익률27%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/11 22:22 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bio-Techne Corporation는 26명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Robert Bamberger | Baird |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |